ID   CNIO BK
AC   CVCL_UU08
DR   IARC_TP53; 24525
DR   Wikidata; Q93456035
RX   CelloPub=CLPUB00464;
RX   PubMed=16888811;
CC   Doubling time: 96 hours (PubMed=16888811).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811).
DI   NCIt; C3194; Liposarcoma
DI   ORDO; Orphanet_69078; Liposarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 8
//
RX   CelloPub=CLPUB00464;
RA   Moneo V.;
RT   "Generation of cellular tools for preclinical validation of antitumor
RT   compounds.";
RL   Thesis PhD (2009); Universidad Autonoma de Madrid; Madrid; Spain.
//
RX   PubMed=16888811; DOI=10.1002/jcb.21073;
RA   Moneo V., Serelde B.G., Fominaya J.M., Martinez-Leal J.F.,
RA   Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C.,
RA   Tercero J.C., Piris M.A., Jimeno J.M., Carnero A.;
RT   "Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged
RT   sarcoma cell lines correlates with mutated p53.";
RL   J. Cell. Biochem. 100:339-348(2007).
//